14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $16.55 $18.63 Wednesday, 24th Apr 2024 ACAD stock ended at $16.59. This is 0.90% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 1.72% from a day low at $16.55 to a day high of $16.84.
90 days $16.55 $27.94
52 weeks $16.55 $33.91

Historical ACADIA Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Feb 12, 2024 $26.17 $26.78 $26.10 $26.76 1 174 074
Feb 09, 2024 $26.00 $26.46 $25.38 $26.36 1 081 465
Feb 08, 2024 $25.32 $25.80 $24.94 $25.68 978 382
Feb 07, 2024 $25.70 $25.73 $24.98 $25.21 961 646
Feb 06, 2024 $25.01 $25.91 $24.86 $25.74 1 256 066
Feb 05, 2024 $24.98 $25.19 $24.52 $25.10 1 168 449
Feb 02, 2024 $25.78 $25.78 $25.07 $25.29 1 095 258
Feb 01, 2024 $26.07 $26.32 $25.61 $26.14 1 125 010
Jan 31, 2024 $26.64 $26.83 $25.67 $25.91 1 829 762
Jan 30, 2024 $27.89 $27.94 $26.72 $26.83 1 517 232
Jan 29, 2024 $27.15 $27.58 $26.52 $27.54 1 184 092
Jan 26, 2024 $27.18 $27.74 $26.88 $26.94 1 038 924
Jan 25, 2024 $27.44 $27.66 $26.92 $27.17 1 960 576
Jan 24, 2024 $29.29 $29.29 $27.02 $27.19 1 759 986
Jan 23, 2024 $28.16 $28.47 $27.56 $28.15 1 427 448
Jan 22, 2024 $27.41 $28.15 $27.28 $27.76 1 241 705
Jan 19, 2024 $27.68 $27.68 $27.01 $27.29 2 317 124
Jan 18, 2024 $28.13 $28.13 $26.99 $27.59 1 431 097
Jan 17, 2024 $28.62 $28.72 $27.52 $27.98 1 653 608
Jan 16, 2024 $28.61 $29.18 $28.28 $28.95 1 391 002
Jan 12, 2024 $29.15 $29.29 $28.44 $28.73 954 566
Jan 11, 2024 $29.02 $29.30 $27.93 $28.80 1 693 783
Jan 10, 2024 $30.68 $31.10 $29.10 $29.30 1 957 722
Jan 09, 2024 $29.66 $30.79 $29.32 $30.66 1 332 242
Jan 08, 2024 $30.01 $30.21 $29.50 $30.13 2 380 515
Click to get the best stock tips daily for free!

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych... ACAD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT